The U.S. Food and Drug Administration (FDA) has granted traditional approval to Jaypirca (pirobrutinib) for the treatment of ...

With FDA approval to treat marginal zone lymphoma (MZL), Bristol Myers Squibb’s Breyanzi has become the first CAR-T therapy ...

With both a label expansion and a conversion to a full approval, Eli Lilly has earned the FDA’s go-ahead to act on the ...

The U.S. Food and Drug Administration on Wednesday granted traditional approval to Eli Lilly and Company’s Jaypirca for ...

Bristol Myers Squibb BMY recently obtained FDA approval for the label expansion of Breyanzi (lisocabtagene maraleucel) for ...

The FDA has approved pirtobrutinib for certain adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.The new indication applies to adults who previously have ...

Researchers at the University of Eastern Finland and their international collaborators have identified key developmental and molecular differences between the two main subtypes of chronic lymphocytic ...

Insights from ASH 2025, including anticipated presentations, key takeaways, and how new research in chronic lymphocytic leukemia affects patient care.

Pirtobrutinib is now FDA-approved for relapsed/refractory CLL/SLL after prior covalent BTK inhibitor therapy, following its 2023 accelerated approval. The BRUIN-CLL-321 trial showed pirtobrutinib ...

Gastroenterologists and pathologists are recognizing nonbloody watery diarrhea owing to 'microscopic colitis' with increasing frequency; this disease is therefore an important clinical and ...